Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis

被引:59
作者
Gertz, MA [1 ]
Lacy, MQ [1 ]
Lust, JA [1 ]
Greipp, PR [1 ]
Witzig, TE [1 ]
Kyle, RA [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA
关键词
D O I
10.1200/JCO.1999.17.1.262
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: primary systemic amyloidosis is an immunoglobulin deposition disorder in which insoluble light chains cause organ dysfunction and death. The established conventional therapy is treatment with melphalan and prednisone. We investigated whether treatment with multiple alkylating agents improved the response rare or survival time, compared with melphalan and prednisone therapy. Patients and Methods: We treated 101 patients with biopsy-proven primary amyloidosis. The patients were randomly assigned to receive melphalan and prednisone (52 patients) or vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (49 patients). patients were stratified according to the presence of cardiac involvement; time from diagnosis to randomization, serum beta(2)-microglobulin level, and whether peripheral neuropathy was the major manifestation of the disease. Results: The median duration of survival after randomization was 29 months, with no differences in survival time between the two groups. There were 29 patients who fulfilled the response criteria: 15 in the vincristine, carmustine, melphalan, cyclophosphamide, and prednisone arm and 14 in the melphalan and prednisone arm. Conclusion: Therapy with multiple alkylating agents did not result in a higher response rate or longer survival time, compared with standard melphalan and prednisone treatment in patients with primary systemic amyloidosis. J Clin Oncol 17:262-267. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 26 条
[1]   RESOLUTION OF PRIMARY AMYLOIDOSIS DURING CHEMOTHERAPY - STUDIES IN A PATIENT WITH NEPHROTIC SYNDROME [J].
COHEN, HJ ;
LESSIN, LS ;
HALLAL, J ;
BURKHOLDER, P .
ANNALS OF INTERNAL MEDICINE, 1975, 82 (04) :466-473
[2]   Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients [J].
Comenzo, RL ;
Vosburgh, E ;
Simms, RW ;
Bergethon, P ;
Sarnacki, D ;
Finn, K ;
Dubrey, S ;
Faller, DV ;
Wright, DG ;
Falk, RH ;
Skinner, M .
BLOOD, 1996, 88 (07) :2801-2806
[3]  
Comenzo RL, 1998, BLOOD, V91, P3662
[4]   Treatment of AL-amyloidosis with dexamethasone plus alpha interferon [J].
Dhodapkar, MV ;
Jagannath, S ;
Vesole, D ;
Munshi, N ;
Naucke, S ;
Tricot, G ;
Barlogie, B .
LEUKEMIA & LYMPHOMA, 1997, 27 (3-4) :351-356
[5]   Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes [J].
Dubrey, SW ;
Cha, K ;
Skinner, M ;
LaValley, M ;
Falk, RH .
HEART, 1997, 78 (01) :74-82
[6]   PERIPHERAL NEUROPATHY AS AN EARLY MARKER OF AL AMYLOIDOSIS [J].
DUSTON, MA ;
SKINNER, M ;
ANDERSON, J ;
COHEN, AS .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (02) :358-360
[7]  
GERTZ MA, 1991, BLOOD, V77, P257
[8]  
GERTZ MA, 1991, J LAB CLIN MED, V118, P33
[9]   BETA2-MICROGLOBULIN PREDICTS SURVIVAL IN PRIMARY SYSTEMIC AMYLOIDOSIS [J].
GERTZ, MA ;
KYLE, RA ;
GREIPP, PR ;
KATZMANN, JA ;
OFALLON, WM .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (05) :609-614
[10]   AMYLOIDOSIS - PROGNOSIS AND TREATMENT [J].
GERTZ, MA ;
KYLE, RA .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 24 (02) :124-138